HealthMyne’s radiomic and quantitative imaging solution was used in a lung carcinoma study that was published in Cancer Control, the company announced recently.

According to a release, the study demonstrated HealthMyne’s quantitative volumetric delineation was consistent and that several radiomic metrics extracted by the tool were significant and robust predictors of response evaluation criteria in solid tumors (RECIST).

The study included 150 patients.